ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
12 hedge funds and large institutions have $1.03M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 0 closing their positions.
9% more funds holding
Funds holding: 11 → 12 (+1)
0.81% more ownership
Funds ownership: 13.2% → 14.01% (+0.81%)
23% less capital invested
Capital invested by funds: $1.35M → $1.03M (-$317K)
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$235K |
| 2 |
DF
Dunhill Financial
London,
United Kingdom
|
+$723 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$186K |
| 2 |
Morgan Stanley
New York
|
-$25.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$17.1K |
| 4 |
Focus Partners Wealth
Boston,
Massachusetts
|
-$5.27K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$2.68K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Focus Partners Wealth
Boston,
Massachusetts
| $348K | -$5.27K | -452 | -1% |
|
|
2
Jane Street
New York
| $346K | +$235K | +20,127 | +121% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $271K | -$186K | -15,970 | -36% |
|
|
4
UBS Group
Zurich,
Switzerland
| $29.7K | -$17.1K | -1,467 | -32% |
|
|
5
Morgan Stanley
New York
| $13.7K | -$25.1K | -2,153 | -60% |
|
|
6
Osaic Holdings
Scottsdale,
Arizona
| $7.24K | -$2.68K | -230 | -23% |
|
|
BBPWM
7
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $6.82K | – | – | – |
|
|
NFSG
8
Newbridge Financial Services Group
Boca Raton,
Florida
| $2.83K | – | – | – |
|
|
DF
9
Dunhill Financial
London,
United Kingdom
| $2.41K | +$723 | +62 | New |
|
10
Wells Fargo
San Francisco,
California
| $2.36K | – | – | – |
|
|
NA
11
NewEdge Advisors
New Orleans,
Louisiana
| $1.42K | – | – | – |
|
12
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$2.65K | -227 | -73% |
|
CNCR Hedge Fund Activity: Q1 2025 in Review
12 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q1 2025, worth a combined $1.03M — down 23% from $1.35M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CNCR positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 6 trimmed.
The largest buyer was Jane Street, adding an estimated $235K. The largest seller was Susquehanna International Group, cutting an estimated $186K.
- 12 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q1 2025, up from 11 in Q4 2024.
- Funds reported $1.03M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q1 2025, down 23% quarter-over-quarter.
- 1 fund opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q1 2025 and 0 closed out, a net change of +1 holder.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q1 2025 was Jane Street, an estimated $235K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q1 2025 was Susquehanna International Group, an estimated $186K sold.
Based on aggregated 13F filings for Q1 2025.